Literature DB >> 10751848

Medical treatment of cystinuria: critical reappraisal of long-term results.

F Barbey1, D Joly, P Rieu, A Méjean, M Daudon, P Jungers.   

Abstract

PURPOSE: We evaluated long-term results of a contemporary medical therapeutic regimen in patients with cystinuria and analyzed factors predictive of therapeutic success.
MATERIALS AND METHODS: A total of 27 adults with cystine urolithiasis were treated at our institution for 1.3 to 32 years (mean 11.6, overall 312 patient-years). We obtained data on the pre-referral period for 274 patient-years overall. Basic therapy included hyperdiuresis and alkalization. The thiols D-penicillamine or tiopronin were added when standard therapy failed to prevent new stones and stone growth or dissolve preexisting stones. X-ray and echography were performed every 4 months during the initial 2 years and every 6 months thereafter.
RESULTS: In the pre-referral period 256 stone episodes occurred and 81 urological procedures were performed in 24 patients (0.93 and 0. 29 per patient-year, respectively). Nine patients were treated with added thiols. During the therapeutic period the incidence of stone episodes decreased to 66 (0.20 per patient-year, p <0.001), while the need for urological procedures decreased to 44 (0.14 per patient-year, p <0.001). No further urological procedures were required in 15 patients, including 4 treated with thiols. However, the remaining 12 patients, including 5 treated with thiols, underwent 1 to 7 procedures each (mean 0.26 per patient-year). In the 2 groups mean daily cystine excretion plus or minus standard deviation at baseline (863 +/- 253 versus 761 +/- 270 mg. daily) and mean urinary pH of about 7.4 did not differ significantly. However, daily urine volume was significantly higher in patients with arrested stone formation (3,151 +/- 587 versus 2,446 +/- 654 ml./24 hours, p = 0.006).
CONCLUSIONS: Our study provides evidence that a regularly followed medical program based on high diuresis and alkalization with second line addition of thiols may arrest or markedly decrease cystine stone formation and preclude the need for urological procedures in more than half of the patients. However, patients poorly compliant with hyperdiuresis remain at risk for recurrence. We suggest that maintaining a daily urine volume of greater than 3 l. is essential for therapeutic success regardless of whether thiol derivatives are administered.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10751848     DOI: 10.1016/s0022-5347(05)67633-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  37 in total

Review 1.  Cystinuria: genetic aspects, mouse models, and a new approach to therapy.

Authors:  Amrik Sahota; Jay A Tischfield; David S Goldfarb; Michael D Ward; Longqin Hu
Journal:  Urolithiasis       Date:  2018-12-04       Impact factor: 3.436

Review 2.  Pharmacotherapy of urolithiasis: evidence from clinical trials.

Authors:  Orson W Moe; Margaret S Pearle; Khashayar Sakhaee
Journal:  Kidney Int       Date:  2010-10-06       Impact factor: 10.612

Review 3.  [Alkaline citrates in urology. A status report].

Authors:  L Rinnab; R E Hautmann; M Straub
Journal:  Urologe A       Date:  2004-04       Impact factor: 0.639

Review 4.  [Prevention of nephrolithiasis. Established strategies and new concepts].

Authors:  M Straub; R E Hautmann
Journal:  Urologe A       Date:  2004-04       Impact factor: 0.639

Review 5.  Cystinuria: mechanisms and management.

Authors:  Donna J Claes; Elizabeth Jackson
Journal:  Pediatr Nephrol       Date:  2012-01-27       Impact factor: 3.714

Review 6.  [Evidence-based pharmacological metaphylaxis of stone disease].

Authors:  M Straub; R E Hautmann
Journal:  Urologe A       Date:  2006-11       Impact factor: 0.639

7.  CUA guideline on the evaluation and medical management of the kidney stone patient - 2016 update.

Authors:  Marie Dion; Ghada Ankawi; Ben Chew; Ryan Paterson; Nabil Sultan; Patti Hoddinott; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2016-11-10       Impact factor: 1.862

Review 8.  [S2k guidelines on diagnostics, therapy and metaphylaxis of urolithiasis (AWMF 043/025) : Compendium].

Authors:  T Knoll; T Bach; U Humke; A Neisius; R Stein; M Schönthaler; G Wendt-Nordahl
Journal:  Urologe A       Date:  2016-07       Impact factor: 0.639

9.  Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children.

Authors:  Ralph J DeBerardinis; Curtis R Coughlin; Paige Kaplan
Journal:  J Urol       Date:  2008-10-31       Impact factor: 7.450

Review 10.  How should patients with cystine stone disease be evaluated and treated in the twenty-first century?

Authors:  Kim Hovgaard Andreassen; Katja Venborg Pedersen; Susanne Sloth Osther; Helene Ulrik Jung; Søren Kissow Lildal; Palle Joern Sloth Osther
Journal:  Urolithiasis       Date:  2015-11-27       Impact factor: 3.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.